from today...
Good news for both companies.
MDxHealth Licensee Exact Sciences Confirms Use of Biomarker and Methylation Technology in its Advanced Colon Cancer Test
DURHAM, NC, and LIEGE, BELGIUM – January 10, 2011 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that Exact Sciences (Nasdaq: EXAS) has confirmed that it is using an MDxHealth methylation biomarker together with MDxHealth’s methylation specific PCR (MSP) platform in Cologuard™, a non-invasive stool-based DNA colon cancer screening test. This confirmation has triggered a milestone payment to MDxHealth from Exact Sciences. MDxHealth will also receive royalties on net sales once the test is commercialized. Under the terms of a licensing agreement announced in August 2010, Exact Sciences has been evaluating several MDxHealth methylation biomarkers, among other markers, as well as the MSP technology in studies with its stool-based colon cancer test.
About MDxHealth
MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology-based molecular diagnostic testing for personalized medicine. The company’s tests are based on proprietary gene methylation technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. MDxHealth collaborates with leading cancer research centers such as Johns Hopkins University, Duke University, Lovelace Respiratory Research Institute, Eastern Virginia Medical School, Cleveland Clinic, Memorial Sloan Kettering, and major European academic medical centers. The company has a number of commercial and collaborative partnerships with LabCorp, Merck & Co./Schering Plough, GlaxoSmithKline Biologicals, Roche, Merck Serono, Qiagen, and other industry leaders. Rating :
(4 Ratings)
